

Outbreak Surveillance and Infection Prevention require accurate typing and characterization of bacterial isolates. Sequence your isolates with the pathogenomics- and AMR-experts at Ares Genetics and rely on the validated, AI powered ARESiSS platform for accurate, comprehensive, and epidemiologically relevant data from microbial isolates.



### Bacterial Isolates or DNA



### DNA extraction



### Sequencing

**Whole genome sequencing**  
using short- or long-read technology

### Validated Accuracy\*

The ARESiSS platform has been validated end-to-end using CLIA-grade processes to ensure accurate and reproducible isolate sequencing results.<sup>1</sup>

## Actionable intelligence on Pathogens and AMR

An industry leading database and AI powered bioinformatics platform convert isolate genome data into epidemiologically actionable information.



### Data Analysis and Interpretation

#### Pathogen Characterization

Typing (cgMLST, MLST)  
AMR marker profiling & annotation

#### Advanced Interpretation

Outbreak Analysis (optional)  
Predictive AST (optional)  
Custom analytics (optional)

**ARESDb** is a comprehensive collection of resistance-associated genes and genetic markers for AMR. ARESDb includes known biomarkers and novel ones identified by our proprietary AI discovery platform. Additionally, ARESDb holds an industry-leading set of curated antibiotic susceptibility profiles and associated genomic information, enabling predictive AST.<sup>2,3</sup>

**ARESiSai** aims to set the Industry Standard for AI powered Infectious disease testing in accordance with FDA guidelines.<sup>4,5</sup>

Ares data analysis enables pathogen identification and antibiotic resistance detection with superior accuracy and in line with FDA requirements for diagnostic antimicrobial susceptibility test systems.<sup>6,7</sup>

Industry leading performance in predictive AST: The award-winning team of Ares data scientists has demonstrated superior accuracy in independent studies, including the first multi-center evaluation of NGS-based predictive AST.<sup>6,8</sup>



### Comprehensive Reporting

#### AREScLOUD

Web portal for Reports & Interpretation

**AREScLOUD** is a web-based, user-friendly portal to Isolate Reports and an interface enabling decentralized NGS-based Isolate Analysis for reference labs and medical centers.

\* For research use only and not for diagnostics purposes.

## Your Benefits



**Accurate surveillance**



**Trace chains of transmission**



**Monitor trends and identify  
the emergence of new threats**



**Improve antimicrobial therapy  
through predictive AST**



**Reduce antibiotic overuse**

## We Offer



**Quality results based on validated  
ARESiSS platform<sup>1</sup>**



**Access to Reports via your  
AREScloud portal**



**Turn-around time of 4–6 Weeks**  
(express services upon request)



Get in touch

[services@ares-genetics.com](mailto:services@ares-genetics.com)  
[www.ares-genetics.com](http://www.ares-genetics.com)



We are part of the OpGen Group company:  
Ares Genetics GmbH | Karl-Farkas\_Gasse 18 | 1030 Vienna | Austria

\* For research use only and not for diagnostics purposes.

## References

1. Lepuschitz, S. et al. Front Microbiol. 2020;11:1883. doi: 10.3389/fmicb.2020.01883.
2. Mahfouz, N. et al. J Antimicrob Chemoth 75, 257 (2020).
3. Galata V. et al. Genomics Proteomics Bioinformatics 2019 Apr;17(2):169-182.
4. US FDA, Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a

Medical Device (SaMD) Action Plan. (2021).

5. Lueftinger, L. et al. Front Cell Infect Microbiol. 2021;11:610348. doi: 10.3389/fcimb.2021.610348.
6. Ferreira, I. et al. J Clin Microbiol. 2020;58(7):e00273-20. doi: 10.1128/JCM.00273-20.
7. Jorgensen JH, Ferraro MJ, Jorgensen JH, Ferraro MJ. 2009. Clin Infect Dis 49:1749-1755.
8. Volz C. et al. Front. Microbiol., 13 (2019) | <https://doi.org/10.3389/fmicb.2019.01671>.